Impact of Increasing PD-L1 Levels on Outcomes to PD-1/PD-L1 Inhibition in Patients With NSCLC: A Pooled Analysis of 11 Prospective Clinical Trials.

Jonathon Vallejo¹, Harpreet Singh^1,2, Erin Larkins¹, Nicole Drezner¹, Biagio Ricciuti³, Pallavi Mishra-Kalyani¹, Shenghui Tang¹, Julia A Beaver⁴, Mark M Awad³

¹Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.

²Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD, USA.

³Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

⁴Clinical Development, Treeline Biosciences, Treeline Biosciences, San Diego, CA, USA.

PubMed PMC DOI PDF

Abstract

BACKGROUND: Programmed death ligand 1 (PD-L1) expression is recognized as a key biomarker in the treatment of non-small cell lung cancer (NSCLC) with anti-PD(L)1 inhibitors. Previous work has highlighted that outcomes in patients with NSCLC treated with anti-PD(L)1 inhibitors generally improve with increasing PD-L1 expression. The objectives of these analyses are to quantitate the effect of PD-L1…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.